Algernon Pharmaceuticals (TSE:AGN) has released an update.
Algernon Pharmaceuticals has successfully completed a non-brokered private placement, securing $408,000 in funding at $0.12 per unit, with insider participation amounting to $77,760. The proceeds from this private placement are earmarked for working capital purposes. Additionally, Algernon is in the news for selling its Ifenprodil research program to Seyltx Inc. for $2 million and a 20% equity stake.
For further insights into TSE:AGN stock, check out TipRanks’ Stock Analysis page.
